Sabitlenmiş Tweet
#Lurbinectedin from @PhrmMar has been granted accelerated approval for patients with relapsed #SCLC based on ORR and DoR.This is the first drug approved in this setting in decades! Proud of the well-done job.
FDA Oncology@FDAOncology
On June 15, FDA granted accelerated approval to lurbinectedin (ZEPZELCA, Pharma Mar SA) for adult patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy. #lcsm Drug label: accessdata.fda.gov/drugsatfda_doc…
English
